BIOMAT Database Logo BIOMAT Database Logo

Natural human interferon alpha given orally has different effects on patients with distinct forms of chronic viral hepatitis B. 1996

J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Georgiades Foundation for Therapy of Chronic Disease, Stafford, TX 77477, USA.

During therapy of chronic viral hepatitis B (CVHB), some patients treated with natural human interferon alpha (nHuIFN-alpha) lozenges failed to respond. These observations triggered studies aimed to determine whether there are markers predicting patients' response to therapy with nHuIFN-alpha lozenges. In these studies, 32 patients with CVHB were involved: 20 males and 12 females, 16-61 years of age with proven persistent hepatitis B viremia (HBV). Patients were evaluated for clinical, biochemical liver function, and virological markers of disease. During 300 days of treatment of the patients received 75-150 IU nHuIFN-alpha daily in form of lozenges. The responders to oral interferon therapy were those who had initially alanine amino transferase (ALAT) level higher than 100 IU (85.7% cure rate) and weak responses were observed among patients who had an initial ALAT level below 100 IU (9.0% response rate). Therefore, ALAT test in patients with CVHB may serve as a predicting indicator of the outcome of IFN lozenges therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Natural human interferon alpha may act differently when given parenterally or orally to patients chronically infected with hepatitis B virus.
January 1996, Archivum immunologiae et therapiae experimentalis,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally.
January 1993, Archivum immunologiae et therapiae experimentalis,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Treatment of fourteen chronic active HBsAg+, HBeAg+ hepatitis patients with low dose natural human interferon alpha administered orally.
January 1993, Archivum immunologiae et therapiae experimentalis,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis.
December 1988, Hepato-gastroenterology,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis.
February 2010, Antiviral research,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B.
February 2003, Auris, nasus, larynx,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Effects of interferon-alpha treatment on hepatitis B virus antigen-specific immunologic responses in patients with chronic hepatitis B.
April 1993, Liver,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
[Interferon alpha and chronic viral hepatitis].
September 1994, La Revue du praticien,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
Effects of interferon-alpha therapy on cardiac function in patients with chronic hepatitis B infection.
November 2004, Heart and vessels,
J A Georgiades, and J Caban, and T Zyrkowska-Bieda, and M Zejc, and U Jonas-Skulina, and A Cieśla
[Evaluation of interferon alpha in treatment of chronic viral hepatitis B].
January 1993, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Copied contents to your clipboard!